The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, published in Gastroenterology. This ...

Credit: Getty Images. Medications for ulcerative colitis include first-line therapy 5-ASA for mild cases as well as immune system–altering biologics for more severe cases. The initial treatment with ...

Ulcerative Colitis Market Summary -- The market size for ulcerative colitis in the leading markets is expected to grow significantly by 2034. -- The United States accounted for the highest ulcerative ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

It’s becoming more common to treat ulcerative colitis with two biologic medications, or a biologic and a small molecule drug.

You’ve followed your ulcerative colitis (UC) treatment plan to a T, and yet you’re still experiencing symptoms that won’t let up — or even seem to be taking a turn for the worse. There’s an ...

Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...